Cost of Melanoma Immunotherapy in India — Per Cycle, Single vs Dual Agent, and Full Course

Most people with melanoma are not candidates when they are diagnosed. A thin melanoma that is removed completely is treated by surgery and follow-up alone. Checkpoint inhibitors are used after complete surgery for high-risk stage III disease, or when melanoma cannot be removed by surgery or has spread.

• Surgery is the treatment for early melanoma — wide local excision, with a sentinel node biopsy where it is indicated. No drug replaces getting that surgery done properly and on time (NCCN Cutaneous Melanoma guidance).
• The adjuvant setting is a fixed 12-month course — offered after complete surgery for resected high-risk stage III disease, to lower the chance of the melanoma returning. It has a defined end date, which is why it can be budgeted in advance.
• The advanced setting is open-ended — for melanoma that cannot be removed by surgery or has spread, treatment continues until the disease progresses, until a side effect makes it unsafe, or up to a planned ceiling of about two years.
• A tissue test still comes before the decision — BRAF mutation testing is done because a positive result opens a targeted-tablet pathway that is a genuine alternative, with a very different cost and side-effect profile.
• Fitness and immune history can rule it out — an active autoimmune condition, ongoing high-dose steroids, an organ transplant or a poor performance status can make a checkpoint inhibitor unsafe whatever the stage.

A cycle is priced by the drug, not by the cancer type. As of August 2026, one cycle of a single-agent checkpoint inhibitor costs roughly ₹50,000 to ₹1,50,000 for a domestic or biosimilar product, and roughly ₹2,00,000 to ₹4,50,000 for an imported reference product. Day care and tests add a little more.

All figures are indicative only, as of August 2026, and are quoted by product class rather than by brand. The real number moves with the product selected, whether the dose is flat or calculated by body weight, the cycle interval and the centre. Immunotherapy is given as day care at CION centres, so a routine cycle carries no inpatient bed charge. Where a dose is weight-based, the bill scales with body weight — that mechanism is explained in weight-based versus fixed dosing and what it does to cost.

Dual checkpoint blockade costs several times more per dose. The second drug is imported, dosed by body weight and has no domestic biosimilar. It is also reported to cause severe immune-related side effects far more often. The choice is made on clinical grounds, and the cost consequence should be explained before you agree.

Response figures are approximate ranges as summarised in NCCN and ESMO melanoma guidance for advanced skin melanoma, and are lower in acral and mucosal subtypes. They describe how often a tumour shrinks; they are not a promise about any individual and they are not survival figures. Dual therapy is chosen because a clinician judges it appropriate, never because a family can afford it — and the extra side-effect burden usually means more consultations, more steroids and a real chance of an admission, all of which sit outside the drug price.

It depends on the setting. Adjuvant treatment after complete surgery is a fixed 12-month course, so it can be budgeted in advance. For melanoma that has spread, the course is open-ended and no honest total can be quoted on day one. Plan against the shorter rows first.

Drug costs only, indicative as of August 2026. Add day-care administration and pre-cycle blood tests for every cycle, and a response-assessment scan roughly every eight to twelve weeks. Response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION, and runs roughly ₹10,000 – ₹25,000 per scan depending on the scan type. If dual therapy is used, add the induction figures from the section above on top of the maintenance rows here.

Cover cannot be assumed. Government schemes work to fixed package ceilings that high-cost immunotherapy commonly sits above. Private insurance usually pays for day-care infusion, subject to sub-limits and pre-authorisation. Manufacturer programmes and a biosimilar switch are the two routes that most often change the number.

• Aarogyasri and Ayushman Bharat PM-JAY — melanoma surgery and radiation packages are established, but high-cost immunotherapy sits in a different bracket. Ask the hospital scheme desk for the current ceiling in writing. What the national scheme does and does not reach is set out on Ayushman Bharat and immunotherapy coverage.
• CGHS, ECHS and ESI — approved rate lists plus prior approval. The approval step often takes longer than the gap between two cycles, so start the paperwork before treatment begins.
• Private health insurance — day-care infusion is payable under most modern policies. Sub-limits, waiting periods, pre-existing-disease clauses and pre-authorisation decide what you actually receive.
• Manufacturer patient-assistance and dose-support programmes — several exist in India. Documentation takes time and applications usually have to be made before cycle one.
• A domestic or biosimilar product where it is clinically appropriate — usually the single largest reduction available. The trade-offs are set out in biosimilar immunotherapy and what it actually saves.
• Section 80DDB tax deduction — the Income Tax Act allows a deduction for specified illnesses including cancer, on a certificate from a specialist. Details are on tax relief on immunotherapy costs.

The cycle bill covers the drug, chair and nursing time, pre-medication and the doctor review. Everything else is billed separately. Melanoma adds two costs other cancers often do not: brain imaging, and long-term skin surveillance after treatment ends.

Ask for an itemised estimate before the first cycle that separates the drug from everything else, and ask specifically what happens to that estimate if an immune-related side effect needs treating. A quote that arrives as one number with no breakdown is not yet something you can plan against.

Five things, in this order. Getting them settled before cycle one is what stops a course being abandoned halfway, which is the worst outcome both clinically and financially.

1. The eligibility answer, in writing. The stage, whether the melanoma was removed completely, whether this is adjuvant or advanced treatment, and the subtype.
2. An itemised estimate. Drug separated from day care, blood tests, scans and the tissue tests. One combined number is not an estimate.
3. Whether a domestic or biosimilar product is appropriate. A clinical question for your oncologist, and usually the largest single reduction if the answer is yes.
4. Who pays if a side effect needs treating. Steroids, extra visits and a possible admission sit outside the cycle price, and outside many scheme packages too.
5. An agreed review point. Usually the first response scan, where continuing becomes a decision rather than a default — including the option of stopping, and the option of not starting at all.

Melanoma is not the only cancer where a test result, not a price list, decides whether immunotherapy is even a question. These pages cover how eligibility is gated elsewhere, what happens when immunotherapy follows radiation, and how the pathway itself runs at CION.

• Acral and Mucosal Melanoma: What Immunotherapy Can and Cannot Do — the subtypes most Indian patients actually have, and why the expected benefit differs.
• Immunotherapy for Nasopharyngeal Cancer — another cancer where a small, specific group is eligible and everyone else is not.
• Immunotherapy After Radiation for Head and Neck Cancer — how sequencing after radiation changes both the plan and the monitoring.
• Bleeding and Airway Risks With Head and Neck Tumours on Immunotherapy — a reminder that the tumour site, not just the drug, sets the risks to watch for.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, side-effect monitoring and cost counselling run as one pathway.

Decisions for Healing, Not Billing

Cost is discussed openly at the first consultation — including the option of not starting immunotherapy at all if the numbers do not work for your family.